[AERI] Aerie Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 38.65 Change: 1.45 (3.9%)
Ext. hours: Change: 0 (0%)

chart AERI

Refresh chart

Strongest Trends Summary For AERI

AERI is in the medium-term down -19% below S&P in 1 month and down -42% below S&P in 1 year. In the long-term up 268% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, is focused on the discovery, development, and commercialization of first-in-class glaucoma therapies. Its lead product candidate, Rhopressa, is a once-daily triple-action eye drop, which demonstrated the ability to reduce intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension in a Phase 2b clinical trial. The company is conducting two Phase 3 registration trials in the U.S. to demonstrate non-inferiority of IOP lowering for Rhopressa compared to timolol, as well as commencing a third safety-only Phase 3 registration trial of Rhopressa in Canada. It also develops once-daily quadruple-action Roclatan, a single drop combination of Rhopressa with latanoprost, which has completed a 28-day Phase 2b clinical trial. In addition, the company is taking preparatory steps for Phase 3 registration trials for Roclatan. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Bedminster, New Jersey.

Fundamental Ratios
Shares Outstanding EPS-3.31 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-15.12
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-30.07% ROE-120.74% ROI
Current Ratio7.63 Quick Ratio Long Term Debt/Equity Debt Ratio0.46
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities35.07 M Cash From Investing Activities6.1 M Cash From Operating Activities-13.31 M Gross Profit
Net Profit-17.24 M Operating Profit-19.64 M Total Assets195.2 M Total Current Assets170.96 M
Total Current Liabilities22.39 M Total Debt124.19 M Total Liabilities146.58 M Total Revenue
Technical Data
High 52 week73.9 Low 52 week33 Last close40.18 Last change0.35%
RSI24.79 Average true range1.98 Beta1.35 Volume623.98 K
Simple moving average 20 days-6.56% Simple moving average 50 days-1.32% Simple moving average 200 days-25.12%
Performance Data
Performance Week-3.76% Performance Month-9.77% Performance Quart-2.12% Performance Half-35.04%
Performance Year-23.54% Performance Year-to-date11.3% Volatility daily2.54% Volatility weekly5.68%
Volatility monthly11.64% Volatility yearly40.31% Relative Volume235.1% Average Volume612.54 K
New High New Low

News

2019-03-18 06:30:00 | Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 Dexamethasone Intravitreal Implant in Patients with Macular Edema Associated with Retinal Vein Occlusion

2019-03-13 12:50:04 | Aerie AERI Receives FDA Nod for Rocklatan to Treat Glaucoma

2019-03-13 07:27:36 | The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie

2019-03-12 18:30:00 | Aerie Pharmaceuticals Announces Full-Year 2019 Net Revenue and Net Cash Burn Guidance

2019-03-12 18:20:00 | Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan™ netarsudil and latanoprost ophthalmic solution 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension

2019-03-07 08:13:36 | Introducing Aerie Pharmaceuticals, The Stock That Zoomed 271% In The Last Three Years

2019-03-05 08:02:09 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

2019-03-05 07:30:00 | Aerie Pharmaceuticals to Present at Two Investor Conferences in March

2019-03-01 08:25:00 | New Research Coverage Highlights Micron Technology, Varian Medical, St. Joe, Himax Technologies, Aerie Pharmaceuticals, and Hexcel — Consolidated Revenues, Company Growth, and Expectations for 2019

2019-02-26 20:40:37 | Edited Transcript of AERI earnings conference call or presentation 25-Feb-19 10:00pm GMT

2019-02-26 10:34:03 | Aerie AERI Q4 Earnings Miss, Rhopressa Gains Traction

2019-02-25 21:13:52 | Aerie Pharmaceuticals Inc AERI Q4 2018 Earnings Conference Call Transcript

2019-02-25 16:01:00 | Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results, Provides 2019 Cash Burn Guidance and Business Update

2019-02-22 13:55:45 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

2019-02-19 07:30:00 | Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Monday, February 25, 2019

2019-02-08 08:04:08 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

2019-02-05 14:25:56 | Mizuho's 9 Best Biotech Stocks to Buy for 2019

2019-02-04 04:56:09 | Aerie Pharmaceuticals Enters Overbought Territory: Is A Drop Coming?

2019-01-18 09:10:02 | Aerie's AERI Eye Care Candidate to Enter Clinical Studies

2019-01-17 11:47:27 | A Spotlight On Aerie Pharmaceuticals, Inc.’s NASDAQ:AERI Fundamentals

2019-01-17 08:06:04 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

2019-01-17 06:30:00 | Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-1105 Dexamethasone Intravitreal Implant

2019-01-17 05:14:00 | How to spot risky biotech companies and six to avoid now

2019-01-09 08:05:38 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

2019-01-07 16:57:09 | Aerie's Rhopressa Succeeds in Study on Japanese Patients

2019-01-04 06:30:00 | Aerie Pharmaceuticals Announces Positive Topline Results of Netarsudil Ophthalmic Solution in Pilot Phase 2 Study Supporting Clinical Development in Japan

2019-01-02 06:30:00 | Aerie Pharmaceuticals Announces Appointment of Ami Bavishi as Director, Investor Relations and Vincent Santucci, Pharm.D., as Director, Scientific Market Access

2018-12-13 08:06:41 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

2018-12-12 14:48:07 | Aerie Division's Prospects Have Analysts Bullish On American Eagle

2018-12-12 00:58:06 | Hedge Funds Are Selling Aerie Pharmaceuticals Inc AERI

2018-12-06 08:46:01 | Should You Get Rid of Aerie Pharmaceuticals AERI Now?

2018-12-04 07:20:00 | Investor Expectations to Drive Momentum within Mirati Therapeutics, comScore, Nuance Communications, Carnival, Aerie Pharmaceuticals, and TrueCar — Discovering Underlying Factors of Influence

2018-11-29 08:06:45 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

2018-11-24 08:05:44 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

2018-11-22 08:05:52 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

2018-11-19 14:08:03 | Mariko Gordon's Top 5 New Buys

2018-11-13 06:26:11 | Aerie Pharmaceuticals AERI: Moving Average Crossover Alert

2018-11-09 08:04:50 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

2018-11-08 16:05:09 | Aerie AERI Q3 Earnings Miss, Rhopressa Gains Traction

2018-11-07 07:30:00 | Aerie Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference

2018-11-07 01:30:11 | Edited Transcript of AERI earnings conference call or presentation 6-Nov-18 10:00pm GMT

2018-11-06 17:55:10 | Aerie Pharmaceuticals AERI Reports Q3 Loss, Tops Revenue Estimates

2018-11-06 16:50:39 | Aerie: 3Q Earnings Snapshot

2018-11-06 16:01:00 | Aerie Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

2018-10-30 07:30:00 | Aerie Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018

2018-10-25 08:30:00 | Report: Exploring Fundamental Drivers Behind Invitae, Aerie Pharmaceuticals, Gevo, Global Medical REIT, Cyclacel Pharmaceuticals, and Toll Brothers — New Horizons, Emerging Trends, and Upcoming Developments

2018-10-24 08:11:09 | Aerie completes Durham HQ expansion

2018-10-23 06:30:00 | Aerie Pharmaceuticals Establishes GMP PRINT® Production Facility in an Expanded Global Headquarters

2018-10-18 12:43:54 | Is There An Opportunity With Aerie Pharmaceuticals Inc’s NASDAQ:AERI 48% Undervaluation?

2018-10-16 08:03:52 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.